Ahn-Gook Pharmaceutical안국약품
001540 · KOSDAQ · ₩001540 · 안국약품
- Market cap
- ₩124B
- Enterprise value
- ₩136B
- P/E
- 5.7×
- P/B
- 0.7×
- Dividend yield
- 6.7%
- ROE
- 12.1%
- Net margin
- 6.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−30.5% from the high
₩7,280Today: ₩9,290 – ₩9,500₩13,650
Returns
- 1W+1.6%
- 1M−4.7%
- 3M−4.7%
- 6M+16.9%
- YTD+12.2%
- 1Y+21.8%
- Volume today
- 30,327
- 1.0× the 20-day average
- Traded today
- ₩285M
- Listed shares
- 13,042,420
- EPS (12 months)
- ₩1,660
- Earnings yield 17.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumFlat-4.8% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Ahn-Gook Pharmaceutical stock overview
Ahn-Gook Pharmaceutical (안국약품, KRX: 001540) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures and sells pharmaceuticals and health functional foods in Korea. Its shares closed at ₩9,490 on Oct 29, 2026, down 0.42% on the day, giving it a market value of ₩124B.
Key facts
- Market cap
- ₩124B
- Sector
- Biotech & Pharma
- Latest price change
- −0.42%
- As of
- Oct 29, 2026
- Main business
- The company manufactures and sells pharmaceuticals and health functional foods in Korea.
Quick answers about Ahn-Gook Pharmaceutical
- What does Ahn-Gook Pharmaceutical do?
- The company manufactures and sells pharmaceuticals and health functional foods in Korea. Its main drugs include Cinechura, Pevarojet, Revotention and Shubajet, with a focus on cough and expectorant and cardiovascular medicines, and its main health functional food is Tobicom, an eye health product sold alongside a growing range of healthcare and beauty items. Its products are distributed through wholesalers to hospitals and pharmacies and through online and offline channels, and it also runs a contract manufacturing business from its production plant in Hwaseong, Gyeonggi Province.
- What is the market cap of Ahn-Gook Pharmaceutical?
- The market capitalisation of Ahn-Gook Pharmaceutical was ₩124B at the close on Oct 29, 2026.
- Who are the largest shareholders of Ahn-Gook Pharmaceutical?
- According to the latest official filings, the largest reported holders are Eo Jin (48.22%, as of Oct 21, 2026).
- When is the next earnings report from Ahn-Gook Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Ahn-Gook Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company manufactures and sells pharmaceuticals and health functional foods in Korea. Its main drugs include Cinechura, Pevarojet, Revotention and Shubajet, with a focus on cough and expectorant and cardiovascular medicines, and its main health functional food is Tobicom, an eye health product sold alongside a growing range of healthcare and beauty items. Its products are distributed through wholesalers to hospitals and pharmacies and through online and offline channels, and it also runs a contract manufacturing business from its production plant in Hwaseong, Gyeonggi Province.
Written by AI from the company's latest annual report.
- Korean name
- 안국약품
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 어진, 박인철 (각자 대표)
- Founded
- Feb 1959
- Listed
- Jun 2000
- Listed shares
- 13,042,420
- Fiscal year ends
- Month 12
- Website
- www.ahn-gook.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- 5%+ holding reportOct 21, 2026
- Major Matters Report (Decision on Acquisition of Tangible Assets)Oct 15, 2026
- 5%+ holding reportSep 11, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- New Facility Investment, etc.Jul 14, 2026
Titles in Korean until English translations are added.
Also known as: Ahn-Gook Pharmaceutical / 안국약품 / 001540 / KRX:001540
Source: KRX statistical information